JP2024518410A5 - - Google Patents

Info

Publication number
JP2024518410A5
JP2024518410A5 JP2023568333A JP2023568333A JP2024518410A5 JP 2024518410 A5 JP2024518410 A5 JP 2024518410A5 JP 2023568333 A JP2023568333 A JP 2023568333A JP 2023568333 A JP2023568333 A JP 2023568333A JP 2024518410 A5 JP2024518410 A5 JP 2024518410A5
Authority
JP
Japan
Prior art keywords
antibody
dose
pharmaceutical product
approximately
product according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518410A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/028063 external-priority patent/WO2022236047A1/en
Publication of JP2024518410A publication Critical patent/JP2024518410A/ja
Publication of JP2024518410A5 publication Critical patent/JP2024518410A5/ja
Pending legal-status Critical Current

Links

JP2023568333A 2021-05-07 2022-05-06 重症筋無力症を治療するための抗cd19抗体の使用 Pending JP2024518410A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163185613P 2021-05-07 2021-05-07
US63/185,613 2021-05-07
US202263303655P 2022-01-27 2022-01-27
US63/303,655 2022-01-27
PCT/US2022/028063 WO2022236047A1 (en) 2021-05-07 2022-05-06 Use of an anti-cd19 antibody to treat myasthenia gravis

Publications (2)

Publication Number Publication Date
JP2024518410A JP2024518410A (ja) 2024-05-01
JP2024518410A5 true JP2024518410A5 (cg-RX-API-DMAC7.html) 2025-05-13

Family

ID=81846343

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568333A Pending JP2024518410A (ja) 2021-05-07 2022-05-06 重症筋無力症を治療するための抗cd19抗体の使用

Country Status (10)

Country Link
US (1) US20240270842A1 (cg-RX-API-DMAC7.html)
EP (1) EP4333987A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024518410A (cg-RX-API-DMAC7.html)
KR (1) KR20240004367A (cg-RX-API-DMAC7.html)
AU (1) AU2022270697A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022133A2 (cg-RX-API-DMAC7.html)
CA (1) CA3217586A1 (cg-RX-API-DMAC7.html)
IL (1) IL308296A (cg-RX-API-DMAC7.html)
MX (1) MX2023012703A (cg-RX-API-DMAC7.html)
WO (1) WO2022236047A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024210360A1 (en) * 2023-01-20 2025-06-26 Viela Bio, Inc. Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
AU3272695A (en) 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
PL403488A1 (pl) 2001-05-24 2013-07-08 Zymogenetics, Inc. Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Cd20에 대한 인간 모노클로날 항체
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
ES2537738T3 (es) 2003-06-05 2015-06-11 Genentech, Inc. Terapia de combinación para trastornos de células B
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
US8323653B2 (en) * 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CN101903403B (zh) * 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
CA2753158A1 (en) * 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
EP3157553A4 (en) 2014-06-16 2018-02-28 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)
WO2017148880A1 (en) 2016-03-01 2017-09-08 F. Hoffmann-La Roche Ag Obinutuzumab variants having altered cell death induction
EP3959241A4 (en) * 2019-04-24 2023-01-25 Viela Bio, Inc. USE OF AN ANTI-CD19 ANTIBODY TO TREAT AN AUTOIMMUNE DISEASE

Similar Documents

Publication Publication Date Title
Sabatelli et al. Pure motor chronic inflammatory demyelinating polyneuropathy
JP6250728B2 (ja) α−2Bアドレナリン受容体作動薬を用いて制御性T細胞を活性化する方法
JP7564347B2 (ja) 多発性硬化症を治療するためのlou064
JP2025507678A5 (cg-RX-API-DMAC7.html)
US20210163955A1 (en) Endomucin inhibitor as an anti-angiogenic agent
Wroblewski et al. Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease
Rommer et al. Repurposing multiple sclerosis drugs: a review of studies in neurological and psychiatric conditions
TW202342099A (zh) 醫藥組合物
JP2023536944A (ja) 疾患の治療におけるbtk阻害剤の使用
Nowak et al. The position of monoclonal antibodies and small molecules in the treatment of thyroid orbitopathy
Giesser Multiple sclerosis: current concepts in management
JP7186214B2 (ja) 自己免疫性神経筋疾患を処置するためのクラドリビンの使用
US20170035735A1 (en) Use Of Enoximone In The Treatment Of Atopic Immune-Related Disorders, In Pharmaceutical Composition As Well As In Pharmaceutical Preparation
US20240270842A1 (en) Use of an anti-cd19 antibody to treat myasthenia gravis
Zanon-Moreno et al. New horizons for the treatment of glaucoma. I: Neuroinflammation and inflammasomes
Ugradar et al. The Use of Biologics for Thyroid Eye Disease: S. Ugradar et al.
US20210322422A1 (en) Use of akt inhibitors in ophthalmology
Pazzola et al. Biologics in vasculitides: Where do we stand, where do we go from now?
KR20180050410A (ko) 항-CD20 및 항-BLyS 항체의 조합물의 투여양생법
Gul et al. Safe, Rapid-Onset, and Sustained Biological Activity of IL-1beta Regulating Antibody XOMA 052 in Resistant Uveitis of Behçet’s Disease: Preliminary Results of a Pilot Trial
Shome et al. Inhibiting the NLRP3 inflammasome pathway: An effective way to treat chronic inflammation in experimental autoimmune uveitis
Khim Myasthenia gravis treatment
Yadav et al. Novel drug delivery system in the management of myasthenia gravis
Akkus et al. Recent treatment guidelines and approach toward autoimmune encephalitis
Hasiri et al. Intra-vitreal injection of methotrexate in experimental endotoxin-induced uveitis in rabbit